Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate
The Pharma Data
JANUARY 31, 2021
The Coalition for Epidemic Preparedness Innovations (CEPI) continues to support Clover’s COVID-19 vaccine candidate and will fund its development through licensure. Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate.
52 
Let's personalize your content